Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab and Methylprednisolone Effects on Endotoxin Response
NCT02252809Phase 1Completed
- Sponsor
- CHU Brugmann
- Start
- Nov 2008
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of adalimumab (3 arms), sponsored by CHU Brugmann. Primary endpoint: sputum cells count at 7 days. Started Nov 2008; status: completed.
02
Drugs
Beyond the preview
Go deeper on NCT02252809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02252809.